[go: up one dir, main page]

CN111163778A - 一种mor受体激动剂药物组合物 - Google Patents

一种mor受体激动剂药物组合物 Download PDF

Info

Publication number
CN111163778A
CN111163778A CN201980004491.8A CN201980004491A CN111163778A CN 111163778 A CN111163778 A CN 111163778A CN 201980004491 A CN201980004491 A CN 201980004491A CN 111163778 A CN111163778 A CN 111163778A
Authority
CN
China
Prior art keywords
pharmaceutical composition
pharmaceutically acceptable
present disclosure
oxaspiro
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980004491.8A
Other languages
English (en)
Other versions
CN111163778B (zh
Inventor
杨晓容
蒋艳霞
陈昊
贺峰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Chengdu Suncadia Pharmaceuticals Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Chengdu Suncadia Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Chengdu Suncadia Pharmaceuticals Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN111163778A publication Critical patent/CN111163778A/zh
Application granted granted Critical
Publication of CN111163778B publication Critical patent/CN111163778B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

本披露中涉及一种MOR受体激动剂药物组合物。具体而言,本披露涉及的MOR受体激动剂药物组合物其包含(1S,4S)‑4‑甲氧基‑N‑(2‑((R)‑9‑(吡啶‑2‑基)‑6‑氧杂螺[4.5]癸烷‑9‑基)乙基)‑1,2,3,4‑四氢萘‑1‑胺或其可药用盐,和磷酸盐缓冲液。本披露中之药物组合物在储存数月之后展现了良好的稳定性。

Description

PCT国内申请,说明书已公开。

Claims (15)

  1. PCT国内申请,权利要求书已公开。
CN201980004491.8A 2018-05-14 2019-05-13 一种mor受体激动剂药物组合物 Active CN111163778B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810455502 2018-05-14
CN2018104555021 2018-05-14
PCT/CN2019/086544 WO2019218953A1 (zh) 2018-05-14 2019-05-13 一种mor受体激动剂药物组合物

Publications (2)

Publication Number Publication Date
CN111163778A true CN111163778A (zh) 2020-05-15
CN111163778B CN111163778B (zh) 2023-01-24

Family

ID=68539514

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980004491.8A Active CN111163778B (zh) 2018-05-14 2019-05-13 一种mor受体激动剂药物组合物

Country Status (3)

Country Link
CN (1) CN111163778B (zh)
TW (1) TW202015678A (zh)
WO (1) WO2019218953A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026007980A1 (zh) * 2024-07-03 2026-01-08 上海海雁医药科技有限公司 一种mor受体激动剂的液体组合物及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017063509A1 (zh) * 2015-10-15 2017-04-20 江苏恒瑞医药股份有限公司 氧杂螺环类衍生物、其制备方法及其在医药上的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090028873A1 (en) * 2007-07-27 2009-01-29 Auspex Pharmaceuticals, Inc. Substituted cyclohexanols
PL3290415T3 (pl) * 2011-03-23 2021-07-19 Trevena, Inc. Ligandy receptora opioidowego oraz sposoby ich stosowania i wytwarzania

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017063509A1 (zh) * 2015-10-15 2017-04-20 江苏恒瑞医药股份有限公司 氧杂螺环类衍生物、其制备方法及其在医药上的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LI,XIN ET AL.: "《Discovery of SHR9352: A Highly Potent G Protein-Based u-Opioid Receptor Agonist》", 《ACS OMEGA》 *

Also Published As

Publication number Publication date
TW202015678A (zh) 2020-05-01
WO2019218953A1 (zh) 2019-11-21
CN111163778B (zh) 2023-01-24

Similar Documents

Publication Publication Date Title
TWI607754B (zh) 醫藥組合
KR20030060771A (ko) 국소용 마취제/아편양약물 제제 및 이들의 용도
EP0069600A2 (en) Pharmaceutical compositions
TW202333675A (zh) 用於治療癌症之組合療法之用途
JP2013545772A (ja) 癌治療に用いられるベムラフェニブとインターフェロンを含む併用療法
JPWO2002013817A1 (ja) シスプラチン耐性癌治療剤
JP2024501372A (ja) 吸入用医薬組成物
TW202003548A (zh) 特利加壓素(terlipressin)組合物及其用途
CN111163778A (zh) 一种mor受体激动剂药物组合物
CN102068697B (zh) 含有阿片类镇痛剂和阿片受体拮抗剂的药用组合物
CN111346081A (zh) 包含正戊酸、吲哚丙酸和正丁酸钠的药物组合物的新用途
WO2020072774A1 (en) Combination therapy for the treatment of uveal melanoma
JP2025015727A (ja) p-ボロノフェニルアラニンを含有する注射液剤
JP2025011312A (ja) p-ボロノフェニルアラニンを含有する注射液剤の析出防止方法
CN114569545B (zh) 一种稳定的米托蒽醌制剂
CN114096269B (zh) 高浓度胰岛素制剂
CN114903849A (zh) 一种稳定的液体组合物及其制备方法
KR0156929B1 (ko) 안정화된수용성펜타미딘염수용액
JP6856813B1 (ja) 亜鉛点滴静注用製剤
US20210046094A1 (en) Compositions and methods for treating pain
JPH07277965A (ja) 医薬物質および投薬方法
RU2833356C1 (ru) СПОСОБ ПРЕДОТВРАЩЕНИЯ ВЫПАДЕНИЯ ОСАДКА В ИНЪЕКЦИОННОМ РАСТВОРЕ, СОДЕРЖАЩЕМ п-БОРОНОФЕНИЛАЛАНИН
WO2025202938A1 (en) Pharmaceutical composition comprising a cgrp receptor antagonist for the treatment of acute migraine
WO2024230460A1 (zh) 五环三萜结构修饰化合物在制备白癜风药物中的应用及新制剂
CN120939018A (zh) 一种jak激酶抑制剂的药物组合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant